NBIX logo

NBIX
Neurocrine Biosciences, Inc.

3,281
Mkt Cap
$15.66B
Volume
259,485.00
52W High
$162.39
52W Low
$121.42
PE Ratio
23.94
NBIX Fundamentals
Price
$156.24
Prev Close
$155.73
Open
$156.86
50D MA
$137.33
Beta
0.76
Avg. Volume
1.18M
EPS (Annual)
$4.67
P/B
4.60
Rev/Employee
$1.43M
$13,528.48
Loading...
Loading...
News
all
press releases
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June Neurocrine Biosciences to Present at Upcoming Investor Conferences in June PR Newswire SAN DIEGO, May 26, 2026 SAN DIEGO, May 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its...
News Placeholder
More News
News Placeholder
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA (valbenazine) Capsules
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA (valbenazine) Capsules Neurocrine Biosciences Presents...
News Placeholder
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics PR Newswire SAN DIEGO, May 18, 2026 Strengthens Neurocrine's...
News Placeholder
Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus
XENE's Q1 loss matches estimates, while phase III azetukalner data, cash growth and late-stage pipeline progress stay in focus.
News Placeholder
Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why
Neurocrine (NBIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
News Placeholder
Citigroup Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price
Citigroup upped their price objective on Neurocrine Biosciences from $242.00 to $246.00 and gave the stock a "buy" rating in a research report on Wednesday...
News Placeholder
Morgan Stanley Forecasts Strong Price Appreciation for Neurocrine Biosciences (NASDAQ:NBIX) Stock
Morgan Stanley upped their price objective on shares of Neurocrine Biosciences from $185.00 to $191.00 and gave the company an "equal weight" rating in a research note on Wednesday...
News Placeholder
Royal Bank Of Canada Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price
Royal Bank Of Canada raised their target price on shares of Neurocrine Biosciences from $176.00 to $180.00 and gave the stock an "outperform" rating in a research report on Wednesday...
News Placeholder
Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, Piper Sandler Analyst Says
Piper Sandler raised their target price on Neurocrine Biosciences from $190.00 to $207.00 and gave the company an "overweight" rating in a report on Wednesday...
News Placeholder
Neurocrine Biosciences' (NBIX) Buy Rating Reiterated at Guggenheim
Guggenheim reiterated a "buy" rating and set a $175.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available